ecancermedicalscience

Short Communication

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

8 Dec 2008
LR Silverman, P Fenaux, GJ Mufti, V Santini, E Hellström-Lindberg, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, D McKenzie, CL Beach

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood 108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol 26 7006). Indeed, the AZA CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from first response to best response was also measured.

Article metrics: 1527 views
339
1188

Related Articles

Marianna Masiero, Derna Busacchio, Paolo Guiddi, Paola Arnaboldi, Gennaro Musi, Ottavio De Cobelli, Florence Didier, Gabriella Pravettoni
Maria Asunción Algarra, Maria José Juan Fita, Sergio Sandiego, Héctor Augusto Aguilar, Pablo Álvarez, Mateo Quispe, Antonio Salvador, Adoración Egido, Javier Lavernia, Isidro Machado, José Rubio Briones, Miguel Ángel Climent
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco
Lekha Madhavan Nair, KM Jagathnath Krishna, Aswin Kumar, Susan Mathews, John Joseph, Francis Vadakkumparambil James